logo
  

Athersys Approved To Start MultiStem Therapy Trial For COVID-19-Induced ARD

athersys 041320

Athersys, Inc. said Monday it has received approval from the U.S. Food and Drug Administration to start a Phase 2/3 trial to assess the safety and efficacy of its MultiStem therapy in patients with moderate to severe acute respiratory distress syndrome or ARDS induced by COVID-19.

According to the World Health Organization as well as other recent clinical and epidemiological data, ARDS is the leading cause of death among COVID-19 infected patients. There are no FDA-approved medicines for the treatment of ARDS.

Athersys plans to open the first clinical sites for recruitment of the MACOVIA study this quarter.

The primary efficacy endpoint of the MACOVIA study will be number of ventilator-free days through day 28 as compared to placebo.

The secondary objectives of this study are to evaluate pulmonary function, all-cause mortality, tolerability and quality of life or QoL among survivors.

The study will enroll about 400 patients and will be conducted at leading pulmonary critical care centers throughout the U.S.

Athersys said it recently completed a Phase 1/2 study evaluating administration of MultiStem to patients with ARDS.

The data from the study met its primary endpoint of tolerability and patients were evaluated for 28 days on key clinical parameters as well as improvement in pulmonary function, Athersys noted.

Patients who received MultiStem experienced less mortality, more ventilator-free days, and more intensive care unit or ICU-free days during the 28-day clinical evaluation period than the patients who received placebo.

Based on data from the study, the FDA recently granted Fast Track designation to the program.

Athersys also said it is in talks with the Biomedical Advanced Research and Development Authority or BARDA to expedite the advancement of MultiStem to treat patients with ARDS resulting from the COVID-19 epidemic and other potential pandemic outbreaks.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The US Centers for Disease Control and Prevention or CDC has ended recommendations for social distancing and quarantine with a view to minimize covid-19's impact on persons, communities, and health care systems. The agency also ended recommendation for test-to-stay in schools, CNN noted. Healthcare major Johnson & Johnson, which is in the middle of a talcum powder fiasco, said it is discontinuing talc-based JOHNSON'S Baby Powder globally in 2023. The company plans to transition to an all cornstarch-based baby powder portfolio. According to the company, the commercial decision to use cornstarch in all its baby powder products was made after conducting an assessment of its portfolio Walt Disney's streaming service Disney+ is rolling out its much-anticipated new ad-supported subscription plan for Disney+ in the U.S. as part of its bid to stem the loss and make its streaming business profitable after the services posted a hefty operating loss of more than $1 billion in the third quarter. It is also raising pricing for its bundled subscription plans with Hulu, ESPN+ and live TV.
Follow RTT